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Abstract
Autism spectrum disorder (ASD) is characterized as a developmental disability caused by abnormalities in brain function. Studies 
link ASD with various physiological abnormalities, such as cerebral hypoperfusion, oxidative stress, inflammation, and mitochon-
drial dysfunction. Studies show that diminished blood flow to the brain demonstrates a connection between several core autistic 
behaviors, and the hypoperfusion generally worsen with age, growing more prevalent in older children. Although hyperbaric oxygen 
therapy (“HBOT”) is not yet approved by the United States Food and Drug Administration ) (“FDA”), several studies performed 
internationally have proven its efficacy in treating people with autism. Even so, the FDA does approve of its use for other medical 
conditions such as decompression sickness (the bends) experienced by divers, treatment of air or gas embolism, carbon monoxide 
poisoning , and thermal burns. Hyperbaric oxygen therapy chambers expose the patient to 100% oxygen (unlike the 21% oxygen 
found in the air we breathe) by increasing the air pressure in the chamber up to three times higher than normal air pressure of 
1 atm. This allows the lungs to take in more than the expected amount of oxygen and thus be distributed throughout the body 
to the cells that are deprived of oxygen. This paper examines the effectiveness of HBOT in children with ASD, by reviewing the 
available research.
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Introduction
Autism spectrum disorder (ASD) is a neurodevelopmen-
tal disorder characterized by “persistent deficits in social 
communication and social interaction across multiple 
contexts and restricted repetitive patterns of behavior, 
interests, or activities,” (APA, 2013). ASD includes autistic 
disorder, pervasive developmental disorder, and Asperger 
syndrome. Approximately 1 out of 110 people in the 
United States are currently affected by ASD (Rice, 2006). 
The cause of ASD is unclear. Although several genetic 
syndromes, such as Fragile X and Rett syndromes, have 
been linked with ASD, the majority of ASD cases are not 
due to a simple single gene or chromosomal disorder; 
studies have estimated that genetic syndromes only ac-
count for 6-15% of ASD cases (Schaefer & Mendelsohn, 
2008). Recently, research and clinical studies in ASD have 
linked physiological abnormalities, such as cerebral hy-
poperfusion, inflammation, oxidative stress, mitochondrial 
dysfunction and immune dysregulation (Rossignol & Frye, 
2012). With this perspective, ASD may consist of physio-
logical irregularities rather than merely a CNS disorder 
(Herbert, 2005). Treating ASD is not a simple matter; 
there are a limited number of treatments. The behavioral 
aspects of ASD are manageable with the help of behavior-
al therapies. Applied behavioral analysis (ABA), specifically, 
has been proven to lead to advances in certain children 
with ASD. In two years, ABA brought about remarkable 
improvements in the IQ and behavioral issues of several 
children with ASD (Lovaas, 1987). After four years, ABA 
researchers at the Wisconsin Early Autism project found 
analogous results of improved IQ and behavior (Sallows 
& Graupner, 2005). Conversely, researchers in Norway 
found that eclectic therapy (a form of psychotherapy) 
was successful in the treatment of children with ASD 
who were observed for only one year. The results proved 
to supersede the effective outcomes of ABA (Eikeseth, 
et al., 2002). When it comes to  cognitive and behavioral 
transformations in children with ASD, behavioral thera-
pies are not an ideal approach, as they are quite time de-
manding. Additional treatments for ASD that aim to treat 
physiological irregularities have been conveyed, yet, a 
majority of these forms of treatments have not been crit-
ically assessed. However, many studies were performed 
to test the effects of HBOT to treat the physiological ab-
normalities possessed by people with ASD, many of which 
have shown promising results.
Methods
The research incorporated in this paper was retrieved 
from original research papers and scholarly articles ob-
tained through Touro College’s library of databases, such 
as ProQuest and EBSCO. Google scholar, and PubMed 
were also used to acquire data. The articles chosen were 
critically assessed, compared, and analyzed to evaluate if 
hyperbaric oxygen therapy is effective for treating autism
History of Hyperbaric Chambers
Hyperbaric air or “air under pressure” is a medical treat-
ment that dates back over 150 years.  In 1662, a British 
physician created a sealed chamber in which the air was 
compressed and decompressed using valves and oxygen. 
This was extraordinary;it preceded the  discovery of 
oxygen and was utilized as a treatment for respiratory 
diseases (Clarke, 2008). The idea of employing pressur-
ized environments developed further in 1879, when the 
French surgeon, Fontaine, built a pressurized mobile op-
erating room. He observed that inhaled nitrous oxide 
had greater efficacy when used under pressure. Patients 
treated in an increased pressure environment were 
not as cyanotic as those treated in standard conditions. 
Additionally, his patients experienced improved oxygen-
ation (Fontaine, 1879). In the early 1900’s, Dr. Orville 
Cunningham, a professor of anesthesia, found a greater 
improvement in heart disease victims when they resided 
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closer to sea level than when they were living at higher 
altitudes. Later, hyperbaric chambers were utilized by the 
military, in the 1940’s, to treat deep-sea divers who expe-
rienced decompression sickness. In the 1950’s, physicians 
first used HBOT during lung and heart surgery, which 
steered to its use for carbon monoxide poisoning in the 
1960’s. Since then, over 10,000 clinical trials and case 
studies have been achieved for several other health-relat-
ed purposes, with the great majority reporting successful 
outcomes (Ohnishi, et al. 2000).
Hyperbaric oxygen therapy (HBOT)
Hyperbaric oxygen therapy (HBOT) is the medical use 
of oxygen in a pressurized environment, and involves 
breathing 100% oxygen while inside a hyperbaric cham-
ber that exhibits pressures greater than sea level (1 at-
mosphere). The increased pressure permits oxygen to 
dissolve and saturate the blood plasma (autonomous of 
hemoglobin), which yields an extensive array of valuable 
physiological and cellular outcomes. This noninvasive 
therapy is the most reliable way to provide ample oxygen 
to all organs of the body. The standard treatment lasts 
for 60-90 minutes, during which the patient lies down 
and breathes regularly (Feldmeier, 2003). The use of hy-
perbaric oxygen treatment (HBOT) was implemented 
as a treatment method for numerous clinical disorders. 
It has been proven in several clinical studies to enhance 
the body’s inherent ability to regenerate and repair. It is 
used as a therapy to facilitate the healing process in both 
chronic and acute disorders. Decompression sickness, 
stroke victims, arterial gas embolism, healing of wounds, 
severe carbon monoxide poisoning and smoke inhalation 
are only some of the common uses of HBOT. However, 
in 2005, researchers began to consider using HBOT to 
improve behavioral and physiological abnormalities found 
in individuals with ASD (Leach, et al. 1998).  This paper will 
evaluate the current data on treating ASD with HBOT. 
First, the effects of HBOT on physiological irregularities 
in children with ASD will be evaluated. Then, the effects 
on autistic behaviors will be examined. Finally, the appar-
ent contrary effects of HBOT in ASD and restrictions of 
studies will be assessed.
Cerebral Hypoperfusion in ASD and the Effects 
of HBOT
Cerebral hypoperfusion is characterized as insufficient 
blood flow in the brain and is one of the common physi-
ological abnormalities possessed by individuals with ASD. 
Positron emission tomography (PET) and single-photon 
emission computed tomography (SPECT) were used in 
studies to discern hypoperfusion exhibited in the brains of 
people with ASD versus normal healthy brains (Bjørklund, 
et al. 2018). Both PET and SPECT scans are types of nu-
clear imaging tests that utilize radioactive tracers to cre-
ate three-dimensional images. However, they differ in the 
radiotracers used. Studies have proven these scans to be 
a reliable measure of cerebral blood flow in observing 
what areas of the brain are receiving more blood flow. 
(Amen, et al. 2011; NIH CC, 2002). Common autistic 
behaviors such as need for consistency (Ohnishi, et al. 
2000), habitual behaviors (Starkstein, et al. 2000), disability 
in processing emotions and facial expressions (Critchley, 
et al. 2000), and delayed language development (Wilcox, 
et al. 2002), are linked to hypoperfusion. Moreover, hy-
poperfusion is related with increasing age in children with 
ASD (Wilcox, et al. 2002). It is possible that HBOT could 
improve cerebral hypoperfusion in ASD. Numerous stud-
ies were completed that evaluated the effects of HBOT 
to treat various neurological disorders, such as chronic 
brain injury and traumatic brain injury. The results of the 
SPECT scans were evaluated before and after the deliv-
ery of HBOT at low pressures (1.3 to 1.5 atm). These 
studies showed significant results (Harch, et al. 2012), 
(Golden, et al. 2002). Histograms correlated to the pre 
and post SPECT scans were analyzed with a widely used 
medical images software called Osirix DICOM. Results 
from both scans showed significant pattern differences 
beneath the cerebral cortex in the central area of white 
matter, known as the centrum ovale. The pre-HBOT im-
ages displayed a larger array of counts in the histograms 
than in the post-HBOT. The narrower range of counts in 
the post-HBOT corresponded to the increase of perfu-
sion to the lacking areas. The effectiveness was studied 
through many areas in addition to SPECT: physical exam, 
symptoms, and psychological measurement (Harch, et al. 
2012). Moreover, numerous case studies have reported 
enhancements in cerebral perfusion after HBOT treat-
ment. One study involved a child with ASD who received 
one hour of HBOT at 1.3 atm and 24% oxygen per day for 
ten days (Heuser, et al. 2002). The SPECT scans revealed 
increased perfusion. However, the effects of ten treat-
ments only lasts several months. For longer lasting effects 
(6-18 months) more treatments are necessary (20-60 
treatments). Behavioral improvements were detected in 
this child including cognitive and memory functions. The 
child became sympathetic, started to point and articulate, 
and interact with others. Another child with ASD, who 
received 40 treatments of HBOT at 1.3 atm and 24% 
oxygen, also presented behavioral improvements, such 
as, improvements in speech and communication and fine 
motor skills (Rossignol, 2008).
Another study involved 108 children with ASD who 
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experienced decreased perfusion in their temporal lobes 
as measured by SPECT scans (Kinaci, et al. 1970). They 
received HBOT at 1.5 atm with 100% oxygen for an hour 
a day for 50 days. After their treatments, SPECT scans 
revealed that 82.40% showed improvements in their 
temporal lobes, 85.26% in their frontal lobes, and 75.75% 
in other areas. Furthermore, clinicians did an Autism 
Treatment Evaluation Checklist (ATEC) on 54 of the in-
dividuals and significant improvements were noted: 85.5% 
in Sociability, 79% in Speech/Language/Communication, 
75.2% in Health/Physical/Behavior, and 87% in Sensory/
Cognitive Awareness. This study revealed major improve-
ments in the physical, behavioral and cerebral perfusion of 
children with ASD after HBOT (Kinaci, et al. 1970). This 
study is reliable due to the large sample size, unbiased 
SPECT imaging, and therapist assessments.
Oxidative Stress in ASD and the Effects of HBOT
Oxidative stress is defined as an imbalance between the 
production of reactive oxygen species (free radicals) and 
antioxidant defenses. Some children with ASD experience 
oxidative stress. Some researchers believe that HBOT in-
directly causes an increase in oxidative stress due to the 
amplified production of reactive oxygen species (“ROS”) 
from the elevated oxygen levels (Alleva, et al. 2005). 
Therefore, they are reluctant to use HBOT on children 
with ASD, since some of them already have elevated oxi-
dative stress levels (Rossignol, et al. 2007). A contributing 
factor to their increased oxidative stress levels might be 
due to the excessive amounts of oxygen supply to their 
cell’s mitochondria, which can escalate the production of 
ROS. In contrast, HBOT has proven to upregulate antiox-
idant enzyme production that can aid with detoxification 
issues found in children with ASD such as glutathione 
peroxidase, superoxide dismutase (Gulec, et al. 2004), 
and catalase (Nie, et al. 2006). The antioxidant enzyme 
level increase can protect against harm initiated by ROS 
(Rossignol, 2007). Additionally, minor elevations in ROS 
created by HBOT can be advantageous, as they increase 
mitochondrial biogenesis (Gutsaeva, et al. 2006). 
Two studies have observed the influences of HBOT 
on oxidative stress in children with autism (Audhya, 
2007; Rossignol, et al. 2007). The first study included ad-
ministering HBOT at 1.3 atm daily to 48 children with 
autism. Catalase, glutathione peroxidase and superoxide 
dismutase (SOD) levels were screened before beginning 
HBOT and again after day 1 and day 32 of HBOT (Audhya, 
2007). Results demonstrated a 1.9-fold increase of the 
original catalase levels after the first day and a 90% im-
provement after 32 days. Glutathione peroxidase showed 
a 1.4-fold increase after 1 day and a 1.2-fold increase after 
32 days from the initial HBOT. Finally, a 4.5-fold increase 
of SOD was observed after 1 day and a 4.7-fold increase 
after 32 days of starting HBOT. The results of HBOT on 
antioxidant enzymes can be considered conditioning. 
The second study involved 18 autistic children from 
ages 3-16. This open label, prospective study included ad-
ministering 40 treatments of HBOT, with 24% oxygen, at 
1.3 atm, to 12 children, and 100% oxygen at 1.5 atm to 6 
children. Blood markers were taken before and after 40 
treatments (Rossignol, et al. 2007). Researchers noticed 
dramatic improvements in speech, socialization, GI func-
tion, and strength. The effects persisted months after the 
study was completed. Furthermore, insignificant chang-
es were seen in plasma-oxidized glutathione levels. This 
proves that oxidative stress markers did not worsen be-
cause oxidized glutathione is transported from within the 
cells when intracellular levels surpass the redox capacity 
(Dickinson and Forman, 2002). However, the intracellu-
lar oxidative stress levels in the children with ASD did 
not diminish with the lower HBOT pressures (Rossignol, 
et al. 2007). The open-label nature of this study and the 
two diverse treatment groups (one group who received 
24% oxygen at 1.3 atm versus the other group who re-
ceived 100% oxygen at 1.5 arm), as well as the absence 
of a control group, are some of the limitations of this 
study. Nonetheless, the prospective nature of this study 
strengthens it. 
Inflammation in ASD and the Effects of HBOT
Some individuals with ASD experience inflammation, such 
as neuroinflammation, gastrointestinal inflammation and 
immune dysregulation as supported by recent studies. 
Numerous studies have conveyed atypical inflammatory 
indicators in children with ASD. For instance, increases 
in Tumor Necrosis Factor-alpha (TNF-alpha) (Chez, et al. 
2007), and neopterin (cellular immune system activation 
marker) (Messahel, et al. 1998), were related in studies 
of children with ASD. Additionally, studies showed that 
children with ASD, who reported having gastrointestinal 
inflammation, have analogous symptoms to one suffering 
from inflammatory bowel disease (IBD) (Ashwood, et 
al. 2003). Anti-inflammatory results were reported after 
treatment with HBOT. A decrease in pro-inflammatory 
cytokines (including TNF-alpha, IL-1 and IL-6) (Weisz, et 
al. 1997), and an increase in counter-inflammatory IL-10 
levels were reported after HBOT (Buras, et al. 2006). 
Moreover, improvements in IBD were reported in a 
systematic review that used HBOT (Rossignol 2012). 
A study reported a decrease in production of interfer-
on-gamma by lymphocytes with HBOT at 2.0 atm/10.5% 
oxygen, but an increase in interferon-gamma with 100% 
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oxygen administered at 1.0 atm (Granowitz, et al. 2002). 
Therefore, it is concluded that the result of HBOT on 
reducing inflammation is facilitated through the pres-
sure-related component and not particularly on the de-
livery of oxygen. 
Unfortunately, a series of recurring events can cause 
amplified inflammation which can lead to escalated cere-
bral hypoperfusion. This may cause hypoxia, which leads 
to production of HIF-1a (hypoxia-inducible factor-1alpha) 
which induces inflammation (Nathan, 2003). HIF-1a is 
fundamental in the innate immune system, as it triggers 
inflammation by myeloid cells (Cramer, et al. 2003). 
The effects of HBOT on biomarkers of inflammation 
in children with ASD were inspected in two prospective 
studies. The first study included 12 children who were 
given 40 treatments of HBOT at 1.3 atm/24% oxygen 
and 6 children who were given HBOT at 1.5 atm/100% 
oxygen. Biomarkers were measured before and after the 
treatments by testing the participants’ blood specimens 
taken before and after the treatments (Rossignol, et al. 
2007). Improvements were seen in C-reactive proteins 
(non-specific inflammation markers), as their levels de-
creased in the total study population (p=0.021). The most 
significant decrease was seen in children with the highest 
levels of C-reactive proteins prior to the study. These 
children also showed behavioral improvements. SRS 
(Social Responsiveness Scale), ABC-C (Aberrant Behavior 
Checklist – Community), and ATEC (Autism Treatment 
Evaluation Checklist) were filled out by the parents and 
were used to calculate the scores for each child before 
and after their treatments. 
The second study measured plasma cytokine levels, in-
cluding some related to inflammation prior to and after 
HBOT. Ten children with ASD participated in this 20 week 
study with 80 sessions of HBOT given to them at 1.5 
atm/100% oxygen (Bent, et al. 2012). Although the study 
reported behavioral improvements, negligible modifica-
tions were observed in cytokines. Yet, the authors men-
tioned that none of the children actually had irregular 
cytokine levels prior to the study, so notable variations 
could not be seen. 
In another study, a child with ASD who suffered from 
eczema and bowel inflammation, with a distended abdo-
men, displayed significant improvements after 40 treat-
ments of HBOT at 1.5 atm and 100% oxygen over the 
course of a month (Rossignol 2008).
Mitochondrial Dysfunction in ASD and the 
Effects of HBOT
Mitochondrial dysfunction is observed in some people 
with ASD (Rossignol & Frye, 2011; Frye & Rossignol, 2011). 
HBOT is considered a possible treatment for mitochon-
drial dysfunction, although treatments for this condition 
are minimal (Rossignol & Frye, 2011). The outcomes of 
HBOT on mitochondrial dysfunction were measured in 
various studies. 
In a controlled study HBOT at 1.5 atm and 100% 
oxygen was administered to 69 patients who obtained 
severe traumatic brain injury (TBI), within 24 hours of in-
jury. Significant increases in brain oxygen concentrations 
were seen, as well as increases in cerebral blood flow 
and reduced CSF lactate levels (elevated CSF lactate is 
an indicator of mitochondrial dysfunction). Results also 
showed improvements in mitochondrial function and 
brain metabolism after contrasting both room air treat-
ment of 21% oxygen and 100% oxygen given at normal 
pressure (1 atm) (Rockswold, et al. 2010).
HBOT can make more electron transport chains in 
mitochondria. In 2008, a study was conducted on healthy 
rat tissue (Kurt, et al. 2008). HBOT was done on the rat 
and the tissues were looked at before and after the treat-
ment. Results showed that the mitochondria were work-
ing more efficiently. Mitochondria work more efficiently 
through physical exercise. During exercise, the cells are 
stressed and mitochondria are making more electron 
transport chains. Similarly, with HBOT, the cells are slight-
ly stressed and they make more electron transport chains 
thereby working more efficiently and experiencing less 
oxidative stress. 
Furthermore, a study was conducted in 2006, which 
showed it is possible to increase the number of mito-
chondria in the brain cells of rats. This phenomenon is 
called mitochondrial biogenesis (Gutsaeva et al. 2006). 
This was not demonstrated in humans, because it would 
require risky brain biopsies to be performed on patients. 
This can be one possible mechanism as to why HBOT is 
working. Although these results seem promising, no clin-
ical studies were performed to test the effects of HBOT 
on mitochondrial dysfunction in children with ASD. 
Behavioral Measurements in ASD and the Effects 
of HBOT
Most of the studies performed using HBOT for chil-
dren with ASD have inquired behavioral rather than 
physiological factors. In a current systematic review, 
two double-blind, arbitrary, controlled trials were re-
viewed regarding the use of HBOT in children with ASD 
(Ghanizadeh, 2012). The first study examined the outcome 
of giving 33 children with ASD, 40 treatments of HBOT 
with 24% oxygen at 1.3 atm, which included 2 treatments 
each day for 5 days a week, over the course of 4 weeks. 
This study was performed in comparison to 29 control 
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children with ASD who were given room air that was 
slightly pressurized (1.03 atm/21% oxygen) (Rossignol, et 
al. 2009). Noteworthy improvements were detected in 
the treated children on the ATEC scales (questionnaire 
that measures changes in severity of ASD in response to 
treatment) by the caregiver, as well as on the CGI scales 
(Clinical Global Impression rating scales: measures the 
severity of symptoms, treatment response and the effec-
tiveness of treatments) by the clinicians and parents. The 
results showed improvements in language, eye contact, 
cognitive attentiveness and overall functioning. Strengths 
of this study comprise of the involvement of 6 medical 
centers (which limited possible biases correlated to a 
specific site study), assessments by blinded parents and 
clinicians and the use of a control group.
The second study examined the outcome of giving 18 
children with ASD, 80 treatments of HBOT with 24% ox-
ygen at 1.3 atm, within a 15 week duration. These results 
were compared to 16 children who were treated with a 
placebo, involving air flowing through a chamber at normal 
pressure. Subsequently, ABA therapy was given to both 
groups, yet insignificant changes were observed using var-
ious behavioral scales (Granpeesheh, et al. 2010). These 
undesirable results can be attributed to the fact that rig-
orous ABA therapy was given during the administration 
of HBOT which did not seem successful (Ghanizadeh, 
2012). On the other hand, this study is reliable because of 
the blinded evaluators as well as the control group. The 
contrasting results can be ascribed to the discrepancies 
among the two controlled trials (Ghanizadeh, 2012). For 
example, the age and quantity differences of the partici-
pants, as well as the magnitude of treatments. One study 
delivered 10 hours of HBOT per week (Rossignol, et al. 
2009). While the other study provided 5 hours per week 
(Granpeesheh, et al. 2010). There were also probable dis-
tinctions in ASD severity.
Antagonistic Properties of HBOT in ASD
Among the many studies performed, minimal unfavorable 
outcomes were reported of HBOT usage for people with 
autism. One study stated that “HBOT was safely admin-
istered to autistic children and all participants were able 
to finish 40 HBOT sessions without any major adverse 
events” (Rossignol, et al. 2007). A different study informed 
minor antagonistic effects, including 4 kids with earaches, 
2 kids with otitis media and other individuals who were 
autonomously affected with insomnia, seizures, lethargy, 
amplified vocal sensitivity and hyperactivity (Bent, et al. 
2012). In a controlled study, one of the participants ex-
perienced frequent urination and a skin rash which the 
doctor attributed to yeast as the causing factor. Other 
participants withdrew from the study, specifically one 
child who experienced regressing symptoms of asth-
ma after several HBOT treatments. The physicians did 
not think the two were related, but removed the child 
as a safeguard. Another child withdrew from the study 
before completing it due to anxiety. One participant in 
the control group experienced diarrhea and abdominal 
swelling, yet still completed the experiment. In addition, 
another control group participant experienced wors-
ening of pre-existing eczema. Seizures or barotrauma, 
however, were not detected in neither the treatment nor 
control groups (Rossignol, et al. 2007). In a study per-
formed on the effects of HBOT in Thai autistic children, 
it was reported in the data analysis that “there was no 
serious adverse effect in any case and tinnitus was a mild 
side effect in one case and it went away in one week” 
(Chungpaibulpatana, et al. 2008). 
According to the FDA, “patients receiving HBOT are 
at risk of suffering an injury that can be mild (such as 
sinus pain, ear pressure, painful joints) or serious (such 
as paralysis, or air embolism). Since hyperbaric chambers 
are oxygen rich environments, there is also a risk of fire” 
(FDA commissioner, 2013) .
Restrictions of the Studies Performed
Most of the studies performed contain restraints that 
contribute to the erratic results among them, including 
the retrospective approaches, the absence of control 
participants and the minimal amount of participants. 
Moreover, the open trials increase bias, as both the par-
ticipants and the researchers are aware which treatment 
is being given. However, two of the controlled studies did 
not contain these restraints. Furthermore, other studies 
utilized observational methods which are not efficient 
when analyzing modifications in memory and attentive-
ness (Jepson, et al. 2011). Unfortunately, the long-term 
effects of HBOT are unknown because once the study 
was complete researchers did not follow up on the 
long-lasting effects. Additionally, a majority of the studies 
focused on behavioral modifications rather than physi-
ological modifications. Earlier studies proved that ABA 
therapy in individuals with autism is only effective when 
done over a substantial period of time. For example, ABA 
therapy studies displayed significant behavioral changes 
over a one to four year duration (Lovaas, 1987; Sallows & 
Graupner, 2005). 
It is common for the physiological modifications seen 
in autistic children treated with HBOT to be observed 
before intellectual and developmental enhancements due 
to the intricacies of brain maturation. Studies have found 
significant physiological improvements after a short time 
70
Malky Meyer
in participants who were treated with HBOT, specifically 
modifications with cerebral hypoperfusion. While most 
of the studies noted behavioral enhancements in sever-
al children with autism, the studies only persisted for a 
few months. This short duration of time is not enough 
to determine the influence HBOT has on development. 
Further studies are necessary to investigate the long last-
ing results of HBOT in people with autism. 
Many studies noted behavioral and physiological ad-
vances when treating autistic children using HBOT. Yet, 
noteworthy developments were not found when re-
searchers from a common group performed two studies 
(Granpeesheh, et al. 2010; Jepson, et al. 2011), and insig-
nificant results were noticed in a different minor study 
(Lerman, et al. 2009). The inconsistent outcomes among 
the studies may be attributed to the autistic children’s 
opposing responses to HBOT (Jepson, et al. 2011). To 
illustrate, children who possess certain physiological ab-
normalities such as mitochondrial dysfunction, cerebral 
hypoperfusion and inflammation might be more prone to 
display improvements. Nevertheless, most of the studies 
performed to test behavioral aspects did not analyze the 
chemical aspects such as levels of oxidative stress or in-
flammatory markers. However, one behavioral study did 
analyze alterations in the levels of cytokine, but insignifi-
cant modifications in cytokines were seen because all the 
participants already had regular cytokine levels prior to 
their HBOT treatment (Bent, et al. 2011).
Further investigation is required including participants 
with ASD who possess specific physiological abnormal-
ities and which analyze variations in these physiological 
issues such as cerebral hypoperfusion and inflammation. 
Noteworthy improvements were related in studies which 
administered HBOT sessions more frequently. This also 
seemed true in studies that used HBOT to treat patients 
with traumatic brain injuries, (Harch, et al. 2012). More 
studies, however, are needed to analyze several HBOT 
factors, such as the ideal oxygen and pressure limits re-
quired to treat patients with ASD.
HBOT in Thailand
In 2008, the first study in Thailand was performed to de-
termine the effects of HBOT to treat autistic children and 
whether it is safe or not (Chungpaibulpatana, et al. 2008). 
The study included 7 Thai autistic children who received 
10 sessions of HBOT once a week at 1.3 atm. Before and 
after the treatments, five areas were evaluated: “1. Social 
development 2. Fine motor and Eye-hand coordination 3. 
Language development 4. Gross motor development 5. 
Self - help skills” (Chungpaibulpatana, et al. 2008). Results 
showed advances within these five domains with 75% of 
children who displayed progress while 25% showed no 
reaction to the treatment.
FDA Approval
Although HBOT is currently being used as a treatment 
method to treat various disorders in Thailand such as 
autism, it has not been clinically verified or cleared by 
the FDA to cure or be successful in the treatment of au-
tism, cancer, or diabetes (FDA, 2013). However, the FDA 
did approve the use of HBOT for several other condi-
tions. These include “treatment of air or gas embolism 
(dangerous ‘bubbles’ in the bloodstream that obstruct 
circulation), carbon monoxide poisoning, decompression 
sickness (‘the bends’), and thermal burns (caused by heat 
or fire),” (FDA, 2013).
Disadvantages
Dr. Paul Claus, medical director of Mayo Clinic’s 
Hyperbaric and Altitude Medicine Program, relates risk 
factors of HBOT. The increased oxygen of the chamber 
supports combustion which poses a risk for fires in the 
facility. Therefore, necessary precautions are taken. The 
patients are required to remove their street clothes since 
polyester is fuel for fire. The patients are provided with 
cotton blend clothing instead. Additionally, the treatments 
are quite expensive; they are approximately $1,500 an 
hour in most hospital settings (Claus, 2017). However, 
if more studies are done documenting improvements of 
HBOT, then hopefully the cost will be covered by the 
healthcare system or insurance companies to further 
benefit those with autism. .
Conclusion
“There is no one-answer for many questions but there 
are many answers for one question. Multiple factors are 
the possible causes of autism. The curative factors may be 
from multidisciplinary approaches,” (Chungpaibulpatana, 
et al. 2008). Numerous studies have demonstrated that 
HBOT is an effective treatment for children with autism. 
The pressures utilized during treatment with HBOT (1.5 
atm/100% oxygen maximum) are proven to improve the 
common physiological abnormalities in individuals with 
ASD; such as, cerebral hypoperfusion, oxidative stress, in-
flammation and mitochondrial dysfunction. Furthermore, 
studies that targeted the behavioral measurements in 
ASD also showed positive results even though most of 
those studies did not use control groups. The two studies 
that did utilize control groups however related opposing 
outcomes. However, multiple crucial variations between 
the trials were noted. Taken together, the studies imply 
that the use of HBOT in children with autism correlates 
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with marginal antagonistic effects and is handled well. In 
conclusion, HBOT is a harmless and possibly beneficial 
treatment for kids with autism. However, additional stud-
ies are necessary before it can become an internationally 
accepted treatment method. Future studies should be 
more specific and directed towards the specific physio-
logical abnormalities within the various ASD subdivisions 
and should use control groups as well to promote effi-
ciency and determine which people can gain from HBOT 
treatment. Furthermore, why don’t the hospitals in 
Thailand publish anything regarding their routine HBOT 
usage? They value intellectual property not academic 
publications. If it were not more clinically effective than 
the use of HBOT would not be used regularly and its 
ineffectiveness would spread like wildfire. Based on the 
studies performed, overall, the use of hyperbaric oxygen 
therapy appears to be a promising treatment for children 
with ASD.
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